Gout Management: Acute and Chronic Treatment
Acute Gout Flare Management
For acute gout attacks, initiate treatment with corticosteroids, NSAIDs, or colchicine within hours of symptom onset, with corticosteroids preferred as first-line therapy due to superior safety profile and lower cost. 1
First-Line Options for Acute Flares:
Corticosteroids (preferred): Prednisolone 35 mg daily for 5 days is effective and generally safer than alternatives 1. Consider as first-line unless contraindicated (systemic fungal infections).
Colchicine: Use LOW-DOSE regimen only: 1.2 mg initially, then 0.6 mg one hour later, followed by 0.5 mg 2-3 times daily 1, 2. High-dose colchicine offers no additional benefit but significantly increases gastrointestinal adverse effects. Reduce dose in chronic kidney disease or with CYP3A4/P-glycoprotein inhibitors.
NSAIDs: Any NSAID is equally effective—indomethacin has no superiority over naproxen or ibuprofen despite traditional preference 1. Avoid in renal disease, heart failure, or cirrhosis.
Critical Timing:
Treatment must begin within 12 hours of symptom onset for optimal efficacy 2. Educate patients to self-medicate immediately when flares begin using a pre-defined treatment plan.
Chronic Gout Management: Urate-Lowering Therapy (ULT)
Allopurinol is the strongly recommended first-line urate-lowering therapy for all patients with gout, including those with CKD stage ≥3, due to proven efficacy, tolerability, safety, and low cost. 3
Starting ULT:
Start allopurinol at ≤100 mg/day (even lower ≤50 mg/day in CKD stage ≥3), then titrate upward every 2-4 weeks to achieve target serum uric acid <6.0 mg/dL 3. Maximum FDA-approved dose is 800 mg/day. Low starting doses significantly reduce risk of allopurinol hypersensitivity syndrome and flare precipitation.
Alternative ULT Agents:
Febuxostat: Start at ≤40 mg/day with dose titration 3. Reserve for allopurinol intolerance or failure. More expensive than allopurinol with similar efficacy.
Probenecid: Start at 500 mg once or twice daily with titration 3. Avoid in CKD stage ≥3—use xanthine oxidase inhibitors instead.
Pegloticase: Strongly recommended AGAINST as first-line therapy 3. Reserve only for refractory tophaceous gout after optimal trials of oral agents fail.
Target Serum Uric Acid:
Maintain serum uric acid ≤6.0 mg/dL 3. Some evidence suggests targeting 180-300 µmol/L (3.0-5.0 mg/dL) for chronic tophaceous gout 4.
Flare Prophylaxis During ULT Initiation
Strongly recommend initiating concomitant anti-inflammatory prophylaxis (colchicine, NSAIDs, or prednisone/prednisolone) when starting ULT and continuing for 3-6 months minimum 3. Continue longer if flares persist.
- Colchicine: 0.5-0.6 mg once or twice daily
- NSAIDs: Low-dose regimen
- Prednisone: Low-dose (e.g., 5-10 mg daily)
Choice depends on patient comorbidities, drug interactions, and contraindications.
Key Clinical Pearls:
Starting ULT During Active Flare:
You can conditionally start ULT during an acute flare rather than waiting for resolution 3. This avoids treatment delays, but ensure adequate anti-inflammatory coverage.
Dose Titration Strategy:
The "start low, go slow" approach is critical—higher starting doses increase flare risk and hypersensitivity reactions without improving long-term outcomes 3. Patients with larger body size and diuretic use require higher allopurinol doses to achieve target.
CKD Considerations:
Despite traditional teaching, patients with CKD often require allopurinol doses >300 mg/day to reach target serum uric acid 3. Start lower (≤50 mg/day) but don't hesitate to titrate upward with monitoring.
Common Pitfall:
Discontinuing ULT after achieving target serum uric acid—gout is a chronic disease requiring lifelong ULT in most patients 5. Stopping therapy leads to recurrent hyperuricemia and flares.
Patient Education:
Emphasize that ULT prevents future attacks but doesn't treat acute flares. Patients must understand the need for both acute anti-inflammatory medications and chronic ULT, as confusion about this dual approach contributes to poor adherence 2, 5.